AR071096A1 - Derivados de la 2-trifluorometilnicotinamida como agentes para aumentar el hdl-colesterol - Google Patents
Derivados de la 2-trifluorometilnicotinamida como agentes para aumentar el hdl-colesterolInfo
- Publication number
- AR071096A1 AR071096A1 ARP090101099A ARP090101099A AR071096A1 AR 071096 A1 AR071096 A1 AR 071096A1 AR P090101099 A ARP090101099 A AR P090101099A AR P090101099 A ARP090101099 A AR P090101099A AR 071096 A1 AR071096 A1 AR 071096A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- group
- cholesterol
- agents
- alkyl
- Prior art date
Links
- 108010023302 HDL Cholesterol Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Son utiles para la preparacion de medicamentos para el tratamiento y/o la profilaxis de enfermedades que pueden tratarse con agentes para aumentar el HDL-colesterol, tal como, de una forma preferible, la dislipidemia. Reivindicacion 1: Compuestos de la formula (1) en donde R1, se selecciona de entre el grupo consistente en hidroxialquilo inferior, cicloalquilo, el cual se encuentra insustituido o sustituido por hidroxi o hidroxialquilo inferior, y CH2-CR9R10-cicloalquilo; R9, es hidrogeno o alquilo interior; R10, es hidrogeno o hidroxi; R2, es hidrogeno; R3, se selecciona de entre el grupo consistente en alcoxialquilo interior, halogenoalquilo interior, y heteroarilalquilo interior, en donde, el grupo heteroarilo, se encuentra insustituido o mono- o disustituido por alquilo interior; R4 y R8, son hidrogeno; R5, R6 y R7, de una forma independiente la una con respecto a la otra, se seleccionan de entre el grupo consistente en hidrogeno, alquilo inferior, halogeno, halogenoalquilo inferior, halogenoalcoxi inferior, alquilsulfonilamino inferior y ciano; y sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08153792 | 2008-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR071096A1 true AR071096A1 (es) | 2010-05-26 |
Family
ID=40601113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090101099A AR071096A1 (es) | 2008-03-31 | 2009-03-27 | Derivados de la 2-trifluorometilnicotinamida como agentes para aumentar el hdl-colesterol |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7897621B2 (es) |
| EP (1) | EP2262770B1 (es) |
| JP (1) | JP5442711B2 (es) |
| KR (1) | KR101249668B1 (es) |
| CN (1) | CN101981009B (es) |
| AR (1) | AR071096A1 (es) |
| AU (1) | AU2009231375A1 (es) |
| CA (1) | CA2717537A1 (es) |
| ES (1) | ES2391371T3 (es) |
| IL (1) | IL208021A0 (es) |
| MX (1) | MX2010010000A (es) |
| PE (1) | PE20091826A1 (es) |
| TW (1) | TW200944504A (es) |
| WO (1) | WO2009121740A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010295288A1 (en) * | 2009-09-21 | 2012-05-03 | Johnson & Johnson | O-benzyl nicotinamide analogs as mGluR5 positive allosteric modulators |
| WO2012031817A1 (en) * | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
| US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
| US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0400208D0 (sv) | 2004-02-02 | 2004-02-02 | Astrazeneca Ab | Chemical compounds |
| MX2007012213A (es) * | 2005-04-06 | 2007-12-10 | Hoffmann La Roche | Derivados de piridin-3-carboxamida como agonistas inversos de canabinoides. |
| US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
| US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
| KR101114704B1 (ko) | 2006-10-04 | 2012-03-14 | 에프. 호프만-라 로슈 아게 | Ｃｂ2 수용체 조절제로서 피라진-2-카복스아마이드 유도체 |
| MX2009003222A (es) | 2006-10-04 | 2009-04-06 | Hoffmann La Roche | Derivados de 3-piridinocarboxamida y 2-pirazinocarboxamida como agentes elevadores de colesterol de lipoproteina de alta densidad. |
-
2009
- 2009-03-16 US US12/404,364 patent/US7897621B2/en not_active Expired - Fee Related
- 2009-03-23 WO PCT/EP2009/053343 patent/WO2009121740A1/en not_active Ceased
- 2009-03-23 JP JP2011502334A patent/JP5442711B2/ja not_active Expired - Fee Related
- 2009-03-23 CA CA2717537A patent/CA2717537A1/en not_active Abandoned
- 2009-03-23 KR KR1020107021707A patent/KR101249668B1/ko not_active Expired - Fee Related
- 2009-03-23 CN CN2009801105525A patent/CN101981009B/zh not_active Expired - Fee Related
- 2009-03-23 AU AU2009231375A patent/AU2009231375A1/en not_active Abandoned
- 2009-03-23 MX MX2010010000A patent/MX2010010000A/es active IP Right Grant
- 2009-03-23 EP EP09727590A patent/EP2262770B1/en not_active Not-in-force
- 2009-03-23 ES ES09727590T patent/ES2391371T3/es active Active
- 2009-03-27 AR ARP090101099A patent/AR071096A1/es unknown
- 2009-03-30 TW TW098110488A patent/TW200944504A/zh unknown
- 2009-03-30 PE PE2009000468A patent/PE20091826A1/es not_active Application Discontinuation
-
2010
- 2010-09-06 IL IL208021A patent/IL208021A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200944504A (en) | 2009-11-01 |
| MX2010010000A (es) | 2010-09-30 |
| CA2717537A1 (en) | 2009-10-08 |
| JP5442711B2 (ja) | 2014-03-12 |
| IL208021A0 (en) | 2010-12-30 |
| AU2009231375A1 (en) | 2009-10-08 |
| WO2009121740A1 (en) | 2009-10-08 |
| US20090247588A1 (en) | 2009-10-01 |
| JP2011516444A (ja) | 2011-05-26 |
| EP2262770A1 (en) | 2010-12-22 |
| PE20091826A1 (es) | 2009-11-25 |
| US7897621B2 (en) | 2011-03-01 |
| CN101981009A (zh) | 2011-02-23 |
| KR20100117142A (ko) | 2010-11-02 |
| EP2262770B1 (en) | 2012-08-01 |
| KR101249668B1 (ko) | 2013-04-01 |
| CN101981009B (zh) | 2013-09-11 |
| ES2391371T3 (es) | 2012-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082914A1 (es) | Heteroarilmetilamidas utiles para tratar enfermedades cardiovasculares y dislipemias, composiciones farmaceuticas que las contienen y proceso de preparacion de los mismos | |
| PE20152033A1 (es) | Heterociclos bicicliclos como inhibidores de fgfr | |
| AR079226A1 (es) | Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer | |
| PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
| PE20191496A1 (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas | |
| MX344669B (es) | Agente antiplaquetas novedoso. | |
| CR11757A (es) | Compuestos de triazina como inhibidores mtor y quinasa pi3 | |
| PE20142456A1 (es) | COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks | |
| CR20110059A (es) | Compuestos organicos | |
| CO6440596A2 (es) | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero de rapamicina | |
| UY35641A (es) | PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO) | |
| CU20140072A7 (es) | Derivados de dihidro-oxazina y dihidro-pirido-oxazina | |
| PE20160844A1 (es) | Compuestos triciclicos como agentes anticancerigenos | |
| AR076360A1 (es) | Derivados de 3,3'-espiroindolinona y su uso en el tratamiento del cancer | |
| PE20150229A1 (es) | Tiazoles sustituidos por carboxamida o sulfonamida y derivados relacionados como moduladores para el receptor nuclear huerfano rory | |
| CU24039B1 (es) | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 | |
| SV2016005171A (es) | Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih | |
| UY35242A (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR062769A1 (es) | Derivados de 5- fenil- nicotilamida | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| UY35617A (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| AR094918A1 (es) | Compuestos de tetrahidropirrolotiazina como inhibidores de bace | |
| DOP2013000027A (es) | Derivados de tetrahidro-pirido-pirimidina | |
| CU20110159A7 (es) | Pirimidinas fusionadas | |
| AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |